SESN vs. INSM, RVNC, MORF, SDGR, XENE, CORT, GLPG, NUVL, BBIO, and AKRO
Should you be buying Sesen Bio stock or one of its competitors? The main competitors of Sesen Bio include Insmed (INSM), Revance Therapeutics (RVNC), Morphic (MORF), Schrödinger (SDGR), Xenon Pharmaceuticals (XENE), Corcept Therapeutics (CORT), Galapagos (GLPG), Nuvalent (NUVL), BridgeBio Pharma (BBIO), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical preparations" industry.
Sesen Bio vs.
Insmed (NASDAQ:INSM) and Sesen Bio (NASDAQ:SESN) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, community ranking, earnings and institutional ownership.
Insmed presently has a consensus price target of $43.33, suggesting a potential upside of 125.23%.
Insmed has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Sesen Bio has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.
Sesen Bio has a net margin of 0.00% compared to Insmed's net margin of -212.33%. Sesen Bio's return on equity of 6.70% beat Insmed's return on equity.
In the previous week, Insmed had 4 more articles in the media than Sesen Bio. MarketBeat recorded 4 mentions for Insmed and 0 mentions for Sesen Bio. Insmed's average media sentiment score of 0.81 beat Sesen Bio's score of 0.00 indicating that Insmed is being referred to more favorably in the media.
Sesen Bio has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Sesen Bio, indicating that it is currently the more affordable of the two stocks.
92.8% of Insmed shares are held by institutional investors. Comparatively, 16.5% of Sesen Bio shares are held by institutional investors. 4.3% of Insmed shares are held by insiders. Comparatively, 3.2% of Sesen Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Insmed received 343 more outperform votes than Sesen Bio when rated by MarketBeat users. Likewise, 65.15% of users gave Insmed an outperform vote while only 59.43% of users gave Sesen Bio an outperform vote.
Summary
Insmed beats Sesen Bio on 10 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SESN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Sesen Bio Competitors List
Related Companies and Tools